Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045590 | 0.92 | SMYD3 (0.36) | RENSMYD3LMNAALDH1A1MAPT | |
| SCHEMBL4038831 | 0.92 | CHRM1 (0.39) | RENSMYD3FKBP1A | |
| SCHEMBL4043749 | 0.91 | SMYD3 (0.35) | SMYD3ALDH1A1FKBP1A | |
| SCHEMBL4039254 | 0.91 | KDM4E (0.38) | LMNAALDH1A1FKBP1A | |
| SCHEMBL4045536 | 0.89 | CTSS (0.41) | REN | |
| SCHEMBL4042418 | 0.89 | ALDH1A1 (0.42) | LMNAALDH1A1FKBP1A | |
| SCHEMBL4044663 | 0.89 | HSD17B10 (0.37) | RENSMYD3LMNAALDH1A1HPGD | |
| SCHEMBL4039288 | 0.88 | FKBP1A (0.35) | SMYD3FKBP1A | |
| SCHEMBL4038283 | 0.87 | ALDH1A1 (0.38) | RENLMNAALDH1A1 | |
| SCHEMBL4039911 | 0.86 | FKBP1A (0.34) | SMYD3FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | REN 1289/4885SMYD3 4011/4885LMNA 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.